CompletedNot Applicable

Accuracy of Cardiac Wearables Devices to Detect Atrial Fibrillation

Switzerland312 participantsStarted 2021-04-06

Plain-language summary

Atrial fibrillation (AF) is the most common cardiac arrhythmia. This study is to assess the heart rhythm device accuracy of five cardiac wearable devices (Apple Watch, Kardia Mobile/Kardia Mobile 6L, Fitbit Sense, Samsung Galaxy Watch 3 and Withings Scanwatch, Withings SA, Model Number: HWA09) and its detection algorithms in identifying AF compared to a nearly simultaneously acquired physician-interpreted 12-lead ECG in a real world cohort of patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All consecutive patients undergoing electrophysiological study, pacemaker or implantable defibrillator (ICD) implantation or electric cardioversion at the University Hospital Basel are eligible for study participation and will be asked to participate Exclusion Criteria: * Use of a radial artery graft for coronary artery bypass grafting * Tattoos located on the skin of the wrist or forearm where wearable device will be placed * Patients receiving hemodialysis through arteriovenous fistula in the upper extremities * Patients with inability to communicate and comply with all study requirements * Patients who refused to participate in the trial

What they're measuring

Heart rhythm device accuracy of cardiac wearable devices

Timeframe: one time assessment at baseline

Heart rhythm device accuracy of physician-interpreted iECG

Timeframe: one time assessment at baseline

Trial details

NCT IDNCT04809922

SponsorUniversity Hospital, Basel, Switzerland

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-01-31

View on ClinicalTrials.gov More Atrial Fibrillation (AF) trials